Renalase Challenges the Oxidative Stress and Fibroproliferative Response in COVID-19

Dijana Stojanovic1, Miodrag Stojanovic2,3, Jelena Milenkovic1

  • 1Department of Pathophysiology, Faculty of Medicine, University of Nis, Nis, Serbia.

Insights

Renalase, a kidney-derived enzyme, shows promise in treating COVID-19 by reducing inflammation and fibrosis. This molecule offers organ protection against cell damage, potentially aiding recovery from severe respiratory illness.

Area of Science:

  • Immunology and Pathology
  • Biochemistry and Molecular Biology
  • Pharmacology and Therapeutics

Background:

  • Coronavirus disease 2019 (COVID-19) pathophysiology involves uncontrolled immune responses, cytokine storms, and oxidative stress, leading to acute respiratory distress syndrome and fibrosis.
  • Current therapeutic strategies for severe COVID-19 focus on anti-inflammatory and antifibrotic treatments to mitigate disease progression and post-infection complications.
  • Identifying novel therapeutic targets is crucial for managing the multifaceted pathology of COVID-19.

Purpose of the Study:

  • To review the scientific rationale for using renalase in experimental models of COVID-19.
  • To explore renalase's potential in targeting acute-phase inflammatory mechanisms and preventing fibrosis progression.
  • To highlight renalase as a potential therapeutic agent for COVID-19 based on its cytoprotective properties.

Main Methods:

  • Review of experimental evidence on renalase's organ-protective effects.
  • Analysis of renalase's molecular pathways, including sirtuin activation and NAD+ level enhancement.
  • Examination of renalase's demonstrated efficacy in alleviating experimentally induced organ fibrosis and adverse remodeling.

Main Results:

  • Renalase exhibits significant organ protection by mitigating inflammation, oxidative stress, necrosis, and apoptosis.
  • Systemic administration of renalase effectively reduces experimentally induced organ fibrosis and prevents adverse remodeling.
  • Renalase activates sirtuins by increasing NAD+ levels, indicating a mechanism for cell protection and survival.

Conclusions:

  • Renalase's cytoprotective mechanisms, including anti-inflammatory and antifibrotic effects, provide a strong rationale for its investigation in COVID-19 models.
  • Targeting acute-phase mechanisms and fibrosis progression with renalase may offer a novel therapeutic approach for severe COVID-19.
  • Further research into renalase's employment in experimental COVID-19 models is warranted to exploit its therapeutic potential.

Related Concept Videos

Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.5K
The Unfolded Protein Response01:37

The Unfolded Protein Response

The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
489